209 related articles for article (PubMed ID: 33596640)
1. The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia.
Erkeland SJ; Stavast CJ; Schilperoord-Vermeulen J; Dal Collo G; Van de Werken HJG; Leon LG; Van Hoven-Beijen A; Van Zuijen I; Mueller YM; Bindels EM; De Ridder D; Kappers-Klunne MC; Van Lom K; Van der Velden VHJ; Langerak AW
Haematologica; 2022 Jan; 107(1):143-153. PubMed ID: 33596640
[TBL] [Abstract][Full Text] [Related]
2. The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL.
Otte M; Stachelscheid J; Glaß M; Wahnschaffe L; Jiang Q; Lone W; Ianevski A; Aittokallio T; Iqbal J; Hallek M; Hüttelmaier S; Schrader A; Braun T; Herling M
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173993
[TBL] [Abstract][Full Text] [Related]
3. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract][Full Text] [Related]
4. T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level.
Patil P; Hillebrecht S; Chteinberg E; López C; Toprak UH; Seufert J; Bernhart SH; Kretzmer H; Bergmann AK; Bens S; Högel J; Müller A; Jebaraj BM; Schrader A; Johansson P; Costa D; Schlesner M; Dürig J; Herling M; Campo E; Stilgenbauer S; Wiehle L; Siebert R
Genes Chromosomes Cancer; 2022 Jul; 61(7):432-436. PubMed ID: 35218115
[TBL] [Abstract][Full Text] [Related]
5. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200c-3p inhibits proliferation and migration of renal artery endothelial cells by directly targeting ZEB2.
Liu Y; Jiang Y; Li W; Han C; Zhou L; Hu H
Exp Cell Res; 2020 Feb; 387(2):111778. PubMed ID: 31881206
[TBL] [Abstract][Full Text] [Related]
7. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
8. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Patil P; Cieslak A; Bernhart SH; Toprak UH; Wagener R; López C; Wiehle L; Bens S; Altmüller J; Franitza M; Scholz I; Jayne S; Ahearne MJ; Scheffold A; Jebaraj BMC; Schneider C; Costa D; Braun T; Schrader A; Campo E; Dyer MJS; Nürnberg P; Dürig J; Johansson P; Böttcher S; Schlesner M; Herling M; Stilgenbauer S; Macintyre E; Siebert R
Genes Chromosomes Cancer; 2020 Apr; 59(4):261-267. PubMed ID: 31677197
[TBL] [Abstract][Full Text] [Related]
9. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.
Zhou X; Men X; Zhao R; Han J; Fan Z; Wang Y; Lv Y; Zuo J; Zhao L; Sang M; Liu XD; Shan B
Cancer Gene Ther; 2018 May; 25(3-4):68-76. PubMed ID: 29302045
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells.
Jiang T; Dong P; Li L; Ma X; Xu P; Zhu H; Wang Y; Yang B; Liu K; Liu J; Xue J; Lv R; Su P; Kong G; Chang Y; Zhao C; Wang L
Oncol Rep; 2017 Jul; 38(1):151-158. PubMed ID: 28534959
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion.
Wasifuddin M; Sabzposh H; Sun L; Wu R; Wang JC
J Investig Med High Impact Case Rep; 2023; 11():23247096231176223. PubMed ID: 37219076
[TBL] [Abstract][Full Text] [Related]
13. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia.
Braun T; Stachelscheid J; Bley N; Oberbeck S; Otte M; Müller TA; Wahnschaffe L; Glaß M; Ommer K; Franitza M; Gathof B; Altmüller J; Hallek M; Auguin D; Hüttelmaier S; Schrader A; Herling M
Cancer Res; 2022 May; 82(9):1818-1831. PubMed ID: 35259248
[TBL] [Abstract][Full Text] [Related]
14. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
15. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
[TBL] [Abstract][Full Text] [Related]
17. A novel fine tuning scheme of miR-200c in modulating lung cell redox homeostasis.
Wu YH; Lin HR; Lee YH; Huang PH; Wei HC; Stern A; Chiu DT
Free Radic Res; 2017 Jun; 51(6):591-603. PubMed ID: 28675952
[TBL] [Abstract][Full Text] [Related]
18. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
[TBL] [Abstract][Full Text] [Related]
19. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
[TBL] [Abstract][Full Text] [Related]
20. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
